|
Colorectal Carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
In this study, primary tumors obtained from 1,129 patients with colorectal cancer were used to measure the mRNA expression levels of the following genes associated with the effects of standard chemotherapy for colorectal cancer: 5-fluorouracil (5-FU)-related thymidylate synthase (TYMS), dihydropyrimidine dehydrogenase (DPYD) and thymidine phosphorylase (TYMP); folate-related dihydrofolate reductase (DHFR), folylpolyglutamate synthase (FPGS) and gamma-glutamyl hydrolase (GGH); irinotecan-related topoisomerase I (TOP1); oxaliplatin-related excision repair cross-complementing 1 (ERCC1); biologic agent-related vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR).
|
26676887 |
2016 |
|
Colorectal Carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
In conclusion, we found no significant evidence that genetic variants in FOLR1, GGH, FPGS and SLC19A1 are associated with the risk of colorectal cancer.
|
20037791 |
2010 |
|
Colorectal Carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
A multivariate logistic regression analysis revealed that high folylpolyglutamate synthase (FPGS) gene expression, low gamma-glutamyl hydrolase (GGH) gene expression and low ATP-binding cassette sub-family C, number 1 (ABCC1) gene expression in CRC tissues were predictive factors for a high reduced folate level after LV administration.
|
19636555 |
2010 |
|
Colorectal Carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Low gene expression of folylpolyglutamate synthase (FPGS) in colorectal mucosa correlates with low folate levels and poor survival of colorectal cancer (CRC) patients.
|
18418463 |
2008 |
|
Colorectal Carcinoma
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, we wanted to evaluate the interaction between MTHFR and thymidylate synthase (TS) and folylpolyglutamate synthase (FPGS) and to investigate the impact of folate concentration on patients with CRC with different MTHFR genotypes.
|
16512993 |
2006 |
|
Colorectal Carcinoma
|
0.360 |
Biomarker
|
disease |
CTD_human |
Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer.
|
15814641 |
2005 |
|
Colorectal Carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
Real-time PCR was used to quantify expression levels of folate-associated genes including the reduced folate carrier (RFC-1), folylpolyglutamate synthase (FPGS), gamma-glutamyl hydrolase (GGH),and thymidylate synthase (TS) in tumor tissue and adjacent mucosa of patients with primary colorectal cancer (n=102).
|
14676127 |
2003 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
We performed a mutation analysis in the coding regions of the FPGS gene and the association between single nucleotide polymorphisms (SNPs) within FPGS in a case-control sample of childhood ALL patients.
|
26107232 |
2015 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
To investigate the correlation between common genetic polymorphisms of folylpolyglutamate synthase (FPGS), gamma-glutamyl hydrolase (GGH), and methylenetetrahydrofolate reductase (MTHFR) and serum levels of methotrexate (MTX) in Chinese children with acute lymphoblastic leukemia (ALL).
|
24908438 |
2014 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.350 |
Biomarker
|
disease |
CTD_human |
This study aimed to evaluated whether the A22G polymorphism in the FPGS gene is associated with an increased risk of acute lymphoblastic leukemia (ALL) and whether it plays a role in increasing the survival of patients with ALL.
|
25013492 |
2014 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Therefore, HDACI-induced FPGS expression increases the accumulation of MTX-PG(3-7) and cytotoxicity in ALL cell lines, which is potentiated by DHFR and TS downregulation.
|
20072153 |
2010 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
We found significantly lower expression of the reduced folate carrier (SLC19A1, an MTX uptake transporter) in E2A-PBX1 ALL, significantly higher expression of breast cancer resistance protein (ABCG2, an MTX efflux transporter) in TEL-AML1 ALL, and lower expression of FPGS (which catalyzes formation of MTXPG) in T-lineage ALL, consistent with lower MTXPG accumulation in these ALL subtypes.
|
15630450 |
2005 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
There was a significant relationship between FPGS mRNA and enzyme activity in lymphoblasts from children with newly diagnosed ALL, and blast FPGS mRNA and activity increased after methotrexate treatment.
|
9224825 |
1997 |
|
Rheumatoid Arthritis
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Folyl polyglutamate synthethase (FPGS) gene polymorphisms may influence methotrexate adverse events in South Indian Tamil Rheumatoid Arthritis patients.
|
31611592 |
2020 |
|
Rheumatoid Arthritis
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
FPGS and ABCB1 genetic variants can influence the outcome in RA patients receiving MTX monotherapy.
|
26652611 |
2016 |
|
Rheumatoid Arthritis
|
0.340 |
Biomarker
|
disease |
BEFREE |
FPGS may have a major role in regulating intracellular polyglutamation of MTX in RA patients receiving low-dose weekly MTX therapy.
|
27752107 |
2016 |
|
Rheumatoid Arthritis
|
0.340 |
Biomarker
|
disease |
CTD_human |
Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis.
|
23897011 |
2013 |
|
Rheumatoid Arthritis
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients.
|
17286537 |
2007 |
|
Colorectal Neoplasms
|
0.310 |
Biomarker
|
group |
CTD_human |
Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer.
|
15814641 |
2005 |
|
Colorectal Neoplasms
|
0.310 |
AlteredExpression
|
group |
LHGDN |
Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients.
|
14676127 |
2003 |
|
L2 Acute Lymphoblastic Leukemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Effect of folylpolyglutamate synthase A22G polymorphism on the risk and survival of patients with acute lymphoblastic leukemia.
|
25013492 |
2014 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Effect of folylpolyglutamate synthase A22G polymorphism on the risk and survival of patients with acute lymphoblastic leukemia.
|
25013492 |
2014 |
|
Reticulosarcoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER case-control study.
|
17119116 |
2007 |
|
Lymphoma, Mixed-Cell
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER case-control study.
|
17119116 |
2007 |
|
Lymphoma, Non-Hodgkin
|
0.300 |
Biomarker
|
disease |
CTD_human |
We observed a decreased risk of NHL over-all with BHMTEx8+453A>T and increased risk with CBS Ex13+41C>T, FPGS Ex15-263T>C, and SHMT1 Ex12+138C>T and Ex12+236C>T.
|
17119116 |
2007 |